🧬 S-1 Filed

Benchling IPO 2026

Biotech R&D cloud platform S-1 filed for 2026 Nasdaq listing. $6.1B valuation, 1,000+ life sciences companies, 120%+ NRR. Founded 2012 in San Francisco.

$6.1B
Valuation
$400M+
ARR (est.)
1,000+
Companies
120%+
Net Revenue Retention
IPO Status
🧬 S-1 Filed — 2026 Target
IPO StatusS-1 Filed
Target ExchangeNasdaq
IPO Timeline2026
Valuation$6.1B (2024 Series F)
Last Funding$100M Series F
Total Raised~$400M
HeadquartersSan Francisco, CA
Founded2012
Key Metrics
$400M+
ARR (est. 2025)
1,000+
Companies
120%+
Net Revenue Retention
8 of Top 20
Pharma as Customers
Biotech R&D Cloud Platform

Benchling is a cloud-based R&D platform for biotech and life sciences companies — essentially a lab operating system. Its software manages experiments, biological samples, workflows, and molecular data for companies developing drugs, food products, agricultural chemicals, and materials. Benchling's platform is used by 8 of the top 20 global pharmaceutical companies and over 1,000 biotechs and life sciences companies. The platform includes an integrated development environment (IDE) for DNA sequence design, protein modeling, and lab automation. Benchling's 120%+ NRR indicates customers are expanding their usage significantly year-over-year — a hallmark of strong product-market fit. Founded by Sachin Das and Stephen Hsu in 2012, Benchling raised from Redpoint, Benchmark, and Thrive Capital.

More Pre-IPO Companies